Dublin, Dec. 20, 2018 (GLOBE NEWSWIRE) -- The "Global Insulin Pens Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The insulin pens market will register a CAGR of close to 9% by 2023.
The increasing focus on development of smart insulin pens for type 2 diabetes is likely to drive growth in the market. Companies are striving to grow in the market by incorporating advanced technologies into their products and services.
Market Overview
Growing incidence of diabetes have increased the demand for insulin pens in the market. Product recalls pose as a biggest threat to the market. Regulatory bodies and companies recalling products can impact the sales and a company's brand image.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies including BD and Eli Lilly, the competitive environment is quite intense. Factors such as the increasing focus on development of smart insulin pens and the incidences of diabetes, will provide considerable growth opportunities to insulin pens manufactures.
BD, Eli Lilly, Sanofi, and Novo Nordisk are some of the major companies covered in this report. With the presence of a considerable number of companies, this market appears to be concentrated.
Report Summary:
According to the report, one of the major drivers for this market is the growing incidence of diabetes. The latest trend gaining momentum in the market is the increasing focus on development of smart insulin pens for type 2 diabetes. Further, the report states that one of the major factors hindering the increasing product recalls.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/research/7lr8l2/global_insulin?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Diabetes Devices , Endocrine and Metabolic Disorders Drugs